​​​​​​​PsA Treatment Options Expand

• by Kathryn Wighton

• March 9, 2026

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.

• by Kathryn Wighton

• February 25, 2026

• 4 min

Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs

• by Marc Hernández-Santacana, Pablo Balado-Simó, Miguel Mansilla-Polo, Josep Riera-Monroig

• July 7, 2026

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

• by Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze-Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar

• July 20, 2026